- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04893434
Novel Imaging Technique to Assess Gynecologic Cancer
Rapid Motion-Robust Quantitative DCE-MRI For The Assessment Of Gynecologic Cancer
This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer.
MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit its use in clinical practice. DCE MRI is a new imaging technique that uses additional computer processing to collect information continuously during scanning, which produces more detailed images faster than traditional MRI, which reduces the risk of movement-related blurring and provides important information about tumor activity.
The DCE MRI scan in this study will be done in a standard MRI scanner, using a contrast agent (gadobutrol; Gadavist®) that has been approved by the FDA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jose Ricardo Otazo Torres, PhD
- Phone Number: 646-608-8282
Study Contact Backup
- Name: Oguz Akin, MD
- Phone Number: 212-639-3458
- Email: akino@mskcc.org
Study Locations
-
-
New Jersey
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen (All protocol activities)
-
Contact:
- Oguz Akin, MD
- Phone Number: 212-639-3458
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Jose Ricardo Otazo Torres, PhD
- Phone Number: 646-608-8282
-
Contact:
- Oguz Akin, MD
- Phone Number: 212-639-3458
-
Principal Investigator:
- Oguz Akin, MD
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau (All protocol activities)
-
Contact:
- Oguz Akin, MD
- Phone Number: 212-639-3458
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Healthy volunteers (for SA1) will be entered into the study if they meet the following criteria:
- Women aged 18 years or older.
- Willing and able to provide informed consent
Patients (for SA2) will be entered into the study if they meet the following criteria:
- Women aged 18 years or older.
- Gynecologic cancer undergoing standard of care pelvic MRI prior to treatment
- Planned treatment with chemoradiation (for SA2b only)
- Willing and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocol.
Exclusion Criteria:
Healthy volunteers (SA1) and patients (SA2) exclusion criteria:
- History of allergic reactions to gadolinium-based contrast agents (GBCAs)
- Women of childbearing potential (WOCBP) must not be pregnant.
- Women must not be breastfeeding.
- Contraindications/risk factors to 3T MRI as per assessed by our departmental "Comprehensive MRI Screening Questionnaire" and "MRI Contrast Dye Questionnaire" (e.g. risk factors associated with magnetic field such as cardiac pacemakers, defibrillators or other devices as per standard institutional policy; and risk factors associated with GBCM such as diabetes, dialysis, breastfeeding)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DCE-MR images with Gadobutrol (GBCA)
10 volunteers will undergo a single DCE-MRI of the normal cervix to fine-tune parameters and test the performance of reconstruction and quantification algorithms.
Goldenangled radial LAVA data will be continuously acquired for 5 minutes and the contrast agent will be injected intravenously after 1 minute (same contrast agent and injection rate.
60 gynecologic cancer patients will be enrolled (inclusion criterion: newly diagnosed gynecologic cancer scheduled for standard of care pelvic MRI for staging).
Data from 30 of the patients will be used to assess repeatability; DCE-MRI will be acquired at baseline and repeated 48 hours (+/- 24 h) later (no therapy between the 2 scans).
Data from the other 30 patients will be used to document treatment induced changes in DCE-MRI; patients in this group will undergo DCE-MRI at baseline and repeated after 2 weeks (+/- 3 days) of completion of chemoradiation treatment.
|
Each patient will undergo 3 Gadavist injections.
The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s.
Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).
All subjects will be imaged on the same 3T MRI scanner (GE Healthcare, USA) at MSK for all examinations.
For SA1, subjects will undergo a single research DCE-MRI exam.
Patients in SA2 will undergo a standard of care pelvic MRI at baseline (which includes DCE-standard) in accordance with standard clinical operating procedures at MSK.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assess changes in Ktrans value
Time Frame: baseline
|
Each MRI sequence will have a DCE-MRI quantitative metric Ktrans value for each of 2 independent readers.
The Ktrans value will be generated from the ROIs placed independently by each radiologists using dedicated software
|
baseline
|
assess changes in Ktrans value
Time Frame: 48 hours
|
Each MRI sequence will have a DCE-MRI quantitative metric Ktrans value for each of 2 independent readers.
The Ktrans value will be generated from the ROIs placed independently by each radiologists using dedicated software
|
48 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Oguz Akin, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 21-038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecologic Cancer
-
University of LouisvilleJames Graham Brown Cancer CenterCompleted
-
Shandong UniversityCompletedGynecologic Cancer | Gynecologic DiseaseChina
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedGynecologic Cancer | Surgery | Anesthesia | Hysterectomy | Gynecologic DiseaseItaly
-
National Cancer Institute, NaplesRecruiting
-
UNC Lineberger Comprehensive Cancer CenterRecruitingGynecologic CancerUnited States
-
Western University, CanadaRecruiting
-
University Health Network, TorontoRecruiting
-
Rutgers, The State University of New JerseyWithdrawn
-
University of PalermoUniversita di Verona; Fondazione Policlinico Universitario A. Gemelli, IRCCSCompletedGynecologic CancerItaly
Clinical Trials on Gadobutrol
-
Fundacion Clinic per a la Recerca BiomedicaCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedPancreatic CancerNetherlands
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveUnited Kingdom
-
BayerCompletedCarotid StenosisFrance, China, United States, Austria, Poland, Australia, Italy, Turkey, Germany, Korea, Republic of, Sweden, Switzerland, Czechia, Argentina
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
BayerCompletedEpidemiologic FactorsGermany
-
BayerCompletedMagnetic Resonance ImagingUnited States, Canada, Germany
-
BayerCompletedRenal Artery ObstructionTaiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
-
BayerCompletedCoronary Artery DiseaseUnited States, Canada, Singapore, Australia
-
BayerCompletedCoronary Artery DiseaseNew Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland